RVL Pharmaceuticals plc Quarterly Debt-to-equity in % from Q3 2019 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
RVL Pharmaceuticals plc quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2023.
  • RVL Pharmaceuticals plc Debt-to-equity for the quarter ending June 30, 2023 was 173 %, a 70.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 173 +71.3 +70.1% Jun 30, 2023
Q1 2023 138 -34 -19.7% Mar 31, 2023
Q4 2022 123 -108 -46.7% Dec 31, 2022
Q3 2022 108 -179 -62.3% Sep 30, 2022
Q2 2022 102 -172 -62.9% Jun 30, 2022
Q1 2022 172 -78.6 -31.3% Mar 31, 2022
Q4 2021 231 -3.16 -1.35% Dec 31, 2021
Q3 2021 287 +48.8 +20.4% Sep 30, 2021
Q2 2021 274 +16.9 +6.58% Jun 30, 2021
Q1 2021 251 +33.8 +15.6% Mar 31, 2021
Q4 2020 234 +67.1 +40.1% Dec 31, 2020
Q3 2020 239 +105 +78.2% Sep 30, 2020
Q2 2020 257 Jun 30, 2020
Q1 2020 217 Mar 31, 2020
Q4 2019 167 Dec 31, 2019
Q3 2019 134 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.